17.06.2016 • NewsDede WillamsIneospolyethylene plant

Unipetrol Breaks Ground for new PE Plant

(c) Srebrina Yaneva
(c) Srebrina Yaneva

Czech petrochemicals and plastics producer Unipetrol has held groundbreaking ceremonies for its new polyethylene plant at Litvinov, scheduled to go on stream in mid-2018 with a capacity of up to 270,000 t/y. The new facility will add 150,000 t/y to the group’s PE capacity, as it will replace an older 120,000 t/y plant and complement another plant with capacity of 200,000 t/y. French engineering contractor Technip is building the new plant, which will use Ineos’ Innovene S technology under license.  

At the same time, Unipetrol said it plans to reacquire Spolana, a Czech-based producer of nylon feedstock caprolactam, fertilizers and PVC from Poland’s Anwil for €1 million.

The Prague-based group, which sold Spolana to Anwil in 2006 – the Polish PVC producer has been seeking to unload it for at least five years –  said it wants to now wants to reintegrate its former subsidiary as part of an internal reorganization scheme, especially with regard to its start-up of the new PVC plant. All of the companies involved belong to Polish chemical conglomerate PKN Orlen.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.